Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

This study is testing a combination of two drugs — camrelizumab (an immunotherapy that helps the immune system attack cancer) and apatinib (a drug that cuts off blood supply to tumors) — in patients with advanced stomach or stomach-esophagus junction cancer that has stopped responding to prior chemotherapy. **You may be eligible if:** - You have confirmed stomach cancer or cancer at the junction of the stomach and esophagus - Your cancer has spread or cannot be surgically removed - Your cancer has progressed after at least one round of standard chemotherapy - You are willing to provide a tumor tissue sample for testing - Your cancer has been tested for HER2 status (and if HER2-positive, you have already received trastuzumab) - You are in good general health and your organs are functioning well - Your life expectancy is more than 12 weeks **You may NOT be eligible if:** - Your cancer is a squamous cell or undifferentiated type - You have active brain metastases or cancer spreading to the lining of the brain - You have an active autoimmune disease - You have significant heart or vascular disease - You have uncontrolled high blood pressure - You had serious bleeding in the digestive tract within the past 3 months - You had a stroke, blood clot, or pulmonary embolism in the past 6 months - You have previously received PD-1/PD-L1 immunotherapy or anti-VEGFR drugs Talk to your doctor to see if this trial is right for you.